Kymera Therapeutics

IRAKIMiDs: A Single Small Molecule Approach to Developing Dual-Function Degraders for B Cell Lymphoma with Multiple Drivers

Kymera’s IRAK4 degrader for hidradenitis suppurativa: Hitting an elusive target hard for a hard-to-treat inflammatory disease

Targeted Protein Degradation Comes of Age (As Featured in LifeSciVC)

Going after the “undruggable”: the STAT3 story

Targeted protein degradation (TPD) is one of the most promising and exciting therapeutic modalities today, with the potential to effectively target disease-causing proteins and signaling pathways that have long been out of reach with conventional therapeutic approaches. These are proteins that either lack catalytic activity and/or have catalytic-independent functions – targets that to date have either gone “undrugged” or have not been adequately addressed.

Protein Degradation: New Rules for Drug Discovery

Breakthroughs in technology have revolutionized how we think about new medicines and have brought life-saving treatments to millions of patients. Yet despite all we’ve learned about genomics and proteomics, we have only begun to scratch the surface when it comes to our knowledge of how to leverage or modify the human bodies’ complex cellular mechanisms.